Kobayashi T, Motoya S, Nakamura S, et al. - For refractory ulcerative colitis, anti-tumor necrosis factor (TNF) agents are the mainstay of long-term treatment. Researchers herein conducted a randomized controlled trial evaluating if patients with ulcerative colitis in remission can safely discontinue anti-TNF agents. Outcomes in patients who continued infliximab were compared with those who discontinued infliximab. They screened 122 patients with ulcerative colitis who were in remission, had been treated with intravenous infliximab (5 mg/kg) every 8 weeks, and had initiated infliximab at least 14 weeks before study enrolment. Of these patients, 95 were randomly assigned to the infliximab-continued group (n = 48) or the infliximab-discontinued group (n = 47). Patients who continued infliximab significantly more frequently showed maintenance of remission relative to those who discontinued. Hence, they emphasize practicing caution when discussing discontinuing infliximab, taking both risk of relapse and efficacy of re-treatment into account.